Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Strata Skin Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 21.70%.
The historical rank and industry rank for Strata Skin Sciences's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:E2O'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -79.57 Med: -37.36 Max: -17.44
Current: -43.31
During the past 13 years, Strata Skin Sciences's highest ROC (Joel Greenblatt) % was -17.44%. The lowest was -79.57%. And the median was -37.36%.
FRA:E2O's ROC (Joel Greenblatt) % is ranked worse than 69.65% of 837
companies
in the Medical Devices & Instruments industry
Industry Median: 4.35
vs FRA:E2O: -43.31
Strata Skin Sciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -13.30% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Strata Skin Sciences ROC (Joel Greenblatt) % Related Terms
Strata Skin Sciences ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Strata Skin Sciences's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:E2O vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Strata Skin Sciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Skin Sciences ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Strata Skin Sciences's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 21.70% mean?
Strata Skin Sciences (FRA:E2O) has a ROC (Joel Greenblatt) % of 21.70% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Strata Skin Sciences and its competitors. According to the industry distribution chart, Strata Skin Sciences ranks #583 out of 837 companies in the Medical Devices & Instruments industry, placing it in the top 69.7%.
Is Strata Skin Sciences' ROC (Joel Greenblatt) % too high?
Strata Skin Sciences' current ROC (Joel Greenblatt) % is 21.70%. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.35. Strata Skin Sciences' value of 21.70% is 398.9% above this industry median. Based on the distribution chart, Strata Skin Sciences ranks #583 out of 837 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Strata Skin Sciences ranks #583 out of 837 companies for ROC (Joel Greenblatt) %. This places Strata Skin Sciences in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 4.35. Strata Skin Sciences' value of 21.70% is 398.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.35, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strata Skin Sciences's current ROC (Joel Greenblatt) % of 21.70% is 398.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Strata Skin Sciences and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Skin Sciences's current ROC (Joel Greenblatt) % is 21.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current ROC (Joel Greenblatt) % of 21.70%. The stock's GF Value™ is €1,526.56, compared to a current price of €3.76 — trading 99.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 21.70% and 398.9% above the Medical Devices & Instruments industry median of 4.35. Strata Skin Sciences' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current ROC (Joel Greenblatt) % is 21.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued.
The current stock price of €3.76 is trading 99.8% below its estimated GF Value™ of €1,526.56.
Key valuation signals for FRA:E2O:
ROC (Joel Greenblatt) %: 21.70%
GF Value™: €1,526.56 vs. price of €3.76 (99.8% below fair value)
Industry Position: 398.9% above the Medical Devices & Instruments median (#583 of 837)
No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score
Get the complete analysis for FRA:E2O
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E2O has been successfully added to your 
